Merck is making a $125 million investment in Moderna as part of a new funding round. "We’re encourage by the potential for RNA-based vaccines," says Eric Rubin, a Merck vice president.
Merck is making a $125 million investment in Moderna as part of a new funding round. "We’re encourage by the potential for RNA-based vaccines," says Eric Rubin, a Merck vice president.